Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is a clinical-stage biotech company with a positive outlook due to its promising pipeline, including GEO-MVA and Gedeptin, as potential solutions for infectious diseases and solid tumors. However, the company's near-term outlook is constrained by limited catalysts and tight capital resources, potentially leading to heightened dilution risk for investors. While the recent $1M registered direct offering highlights funding constraints, the company's intellectual property foundation has been strengthened. Consequently, the company's rating has been lowered from Buy to Hold, and its price target has been removed.

Bears say

Geovax Labs is facing financing risk due to a constrained balance sheet, despite the potential value and exclusive license of its cancer treatment Gedeptin. Additionally, the company's focus on its vaccine candidate GEO-MVA may give it a differentiated role in the market, but its balance sheet remains a limiting factor until it can secure additional capital or strategic support. The company's modest financing and potential for future dilution suggest a need to carefully manage capital and clinical execution in order to successfully advance its products.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.